Published in Emerg Infect Dis on June 01, 2009
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Multidrug resistant acinetobacter. J Glob Infect Dis (2010) 1.94
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy (2010) 1.59
Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol (2011) 1.58
Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun (2010) 1.54
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One (2012) 1.32
Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother (2013) 1.17
Photodynamic inactivation of Acinetobacter baumannii using phenothiazinium dyes: in vitro and in vivo studies. Lasers Surg Med (2010) 1.12
Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine (2012) 1.01
Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother (2012) 0.98
Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog (2015) 0.93
DNA microarray for genotyping antibiotic resistance determinants in Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother (2013) 0.88
Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy. Int J Antimicrob Agents (2011) 0.82
Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med (2016) 0.82
Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients. Biomed Res Int (2014) 0.79
Antimicrobial Activity of Gallium Protoporphyrin IX against Acinetobacter baumannii Strains Displaying Different Antibiotic Resistance Phenotypes. Antimicrob Agents Chemother (2015) 0.79
Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother (2014) 0.79
Activation of phenotypic subpopulations in response to ciprofloxacin treatment in Acinetobacter baumannii. Mol Microbiol (2014) 0.79
Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii. Int J Infect Dis (2015) 0.78
In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics. J Mol Model (2012) 0.77
Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity. Ann Clin Microbiol Antimicrob (2010) 0.77
Clinical Variants of the Native Class D β-Lactamase of Acinetobacter baumannii Pose an Emerging Threat through Increased Hydrolytic Activity against Carbapenems. Antimicrob Agents Chemother (2016) 0.77
The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity. Protein Sci (2016) 0.76
Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents. PLoS One (2015) 0.76
Optimal therapy for multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis (2010) 0.75
Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient. Transpl Infect Dis (2015) 0.75
Molecular Epidemiology of Multi-Drug Resistant Acinetobacter baumannii Isolated in Shandong, China. Front Microbiol (2016) 0.75
Essential Oils and Their Components as Modulators of Antibiotic Activity against Gram-Negative Bacteria. Medicines (Basel) (2016) 0.75
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis (2006) 7.29
Tuberculosis. Lancet (2007) 5.45
A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis (2007) 3.39
High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother (2007) 2.82
Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2007) 1.81
Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother (2008) 1.08
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis (2010) 35.92
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med (2009) 10.60
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 9.05
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int (2005) 5.49
Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother (2010) 5.35
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol (2005) 5.26
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis (2002) 4.08
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother (2012) 3.80
Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis (2002) 3.65
A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis (2007) 3.39
Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev (2007) 3.18
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase. Clin Infect Dis (2011) 3.06
A new marker of sepsis post burn injury?*. Crit Care Med (2014) 3.05
The safety of voriconazole. Clin Infect Dis (2002) 2.93
Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis (2007) 2.90
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis (2012) 2.88
Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother (2008) 2.88
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet (2003) 2.78
Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis (2009) 2.75
Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother (2012) 2.68
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol (2005) 2.43
Aerosolization of Acinetobacter baumannii in a trauma ICU*. Crit Care Med (2013) 2.41
PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol (2003) 2.35
Oral hydrogen water prevents chronic allograft nephropathy in rats. Kidney Int (2009) 2.35
Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis (2007) 2.31
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother (2006) 2.23
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev (2012) 2.18
Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity (2011) 2.15
Gram-negative resistance: can we combat the coming of a new "Red Plague"? Med J Aust (2013) 2.12
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet (2002) 2.09
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis (2012) 2.08
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother (2008) 2.03
Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis (2011) 2.02
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother (2006) 1.99
Escherichia coli producing CTX-M-2 beta-lactamase in cattle, Japan. Emerg Infect Dis (2004) 1.98
Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob Agents Chemother (2006) 1.98
Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS One (2011) 1.94
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother (2009) 1.94
Antibiotic resistance: a survey of physician perceptions. Arch Intern Med (2002) 1.91
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Global spread of multiple aminoglycoside resistance genes. Emerg Infect Dis (2005) 1.88
Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis (2009) 1.87
Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol (2008) 1.85
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.80
Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant (2009) 1.78
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil. Antimicrob Agents Chemother (2007) 1.78
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother (2006) 1.74
Leptospirosis after recreational exposure to water in the Yaeyama islands, Japan. Am J Trop Med Hyg (2005) 1.73
Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis (2010) 1.73
Antibiotic resistance--what's dosing got to do with it? Crit Care Med (2008) 1.67
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother (2007) 1.66
Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan. Antimicrob Agents Chemother (2004) 1.65
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother (2009) 1.64
Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents (2007) 1.64
Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A beta-lactamase, GES-4, possessing a single G170S substitution in the omega-loop. Antimicrob Agents Chemother (2004) 1.64
Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis (2010) 1.62
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol (2011) 1.58
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 1.57
Striving for normalcy: symptoms and the threat of rejection after lung transplantation. Soc Sci Med (2004) 1.56
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. Antimicrob Agents Chemother (2008) 1.53
Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 1.52
Coproduction of 16S rRNA methyltransferase RmtD or RmtG with KPC-2 and CTX-M group extended-spectrum β-lactamases in Klebsiella pneumoniae. Antimicrob Agents Chemother (2013) 1.50
Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl (2006) 1.49
Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet (2010) 1.49
Genetic environments of the rmtA gene in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother (2004) 1.47
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev (2013) 1.45